A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Summary

The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.

Timeline

Start

2003-04

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.”

Drugs

Indications